Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 2942-10-1 | MDL No. : | MFCD01325561 |
Formula : | C7H4ClNS | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | AIBQGOMAISTKSR-UHFFFAOYSA-N |
M.W : | 169.63 | Pubchem ID : | 351738 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.63 |
TPSA : | 41.13 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.46 cm/s |
Log Po/w (iLOGP) : | 2.09 |
Log Po/w (XLOGP3) : | 2.64 |
Log Po/w (WLOGP) : | 2.95 |
Log Po/w (MLOGP) : | 2.11 |
Log Po/w (SILICOS-IT) : | 3.83 |
Consensus Log Po/w : | 2.72 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.22 |
Solubility : | 0.102 mg/ml ; 0.000601 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.15 |
Solubility : | 0.119 mg/ml ; 0.000701 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.58 |
Solubility : | 0.0447 mg/ml ; 0.000264 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.97 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | With sodium nitrite In 1,2-dichloro-ethane at 110℃; for 60 h; Sealed tube | It was added in a closed reaction vessel 0.3mmol 2-amino-6-chlorobenzothiazole, 0.6mmol sodium nitrite, 3mL1,2- dichloroethane,the reaction mixture was stirred at 110 reaction conditions 60 hours.After the reaction was stopped, cooled to room temperature, the reactionmixture was added 10mL diluted with dichloromethane, filtration and stripped ofsolvent under reduced pressure, the residue was purified by columnchromatography, eluent V (petroleum ether) / V (ethyl ester) = 6/1, to give6-chlorobenzothiazole, yield 89percent. |
59% | Stage #1: With phosphoric acid; sodium nitrite In water at -10℃; for 2 h; Stage #2: With hypophosphorous acid In water at -5 - 20℃; |
General procedure: Thiazoles (1b-f, j) were prepared from 2-aminothiazoles according to the reported procedure with slight modifications. 24 To a mechanically-stirred solution of 2-amino-6-chlorobenzothiazole (4 g, 21.7 mmol, 1.0 equiv) in 84percent aq phosphoric acid (80 mL) was added a solution of sodium nitrite (9.0 g, 13 mmol, 6.0 equiv) in water (28 mL) dropwise below the surface at -10 °C. After stirring at -10 °C for another 2 h, a 50percent aq solution of hypophosphorous acid (60 mL) was added dropwise to the resulting thick syrup mixture at -5 °C. The reaction mixture was warmed to room temperature, stirred overnight, and then diluted with water (300 mL). Na2CO3 was added portionwise to adjust to pH=8 and extracted with DCM. The organic phase was dried over Na2SO4, concentrated under vacuum, and purified over column chromatography (petroleum ether/EtOAc=100:1) to give 6-chlorobenzothiazole as white solid (2.2 g, 59percent yield). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
72% | Stage #1: With 1,8-diazabicyclo[5.4.0]undec-7-ene In 1-methyl-pyrrolidin-2-one at 70℃; for 0.5 h; Schlenk technique Stage #2: With phenylsilane In 1-methyl-pyrrolidin-2-one at 60℃; for 18 h; Schlenk technique |
General procedure: A tube-type Schlenk flask was charged with 0.045 mmol of catalyst D, 0.045 mmol of 1,8-diazabicyclo[5.4.0]undec-7-ene (7μL), and 1mL of N-methylpyrrolidone. The solution was stirred under nitrogen atmosphere at 60–70°C for 30 min. And, 2mL of N-methylpyrrolidone was added, followed by addition of a balloon charged with carbon dioxide gas. The solution was stirred at 60–70°C for 30 min. Then, 2-aminobenzenethiol derivatives (0.5 mmol), phenylsilane (1.5 mmol) dissolved in 0.5mL of N-methylpyrrolidone was added to the mixture. Reaction was carried out at 60–70°C for 18–30h. After the solution was cooled to room temperature, purification by flash chromatography on silica gel with n-hexane and ethyl acetate afforded benzothiazole derivatives. |
[ 4146-24-1 ]
6-Chloro-2-methylbenzo[d]thiazole
Similarity: 0.89
[ 3622-23-9 ]
2,6-Dichloro-1,3-benzothiazole
Similarity: 0.87
[ 3507-17-3 ]
2-Bromo-6-chlorobenzo[d]thiazole
Similarity: 0.86